FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
FibroGen (NASDAQ: FGEN) announced that CEO Thane Wettig will participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida, on June 10, 2024, from 10:00-10:35 AM ET.
The company will also have one-on-one meetings with investors during the event. A live audio webcast will be accessible through the FibroGen Investor webpage, with a replay available for 90 days.
- CEO Thane Wettig's participation in a high-profile event like the Goldman Sachs Global Healthcare Conference can enhance visibility and investor interest.
- One-on-one investor meetings may lead to increased investor confidence and potential investment opportunities.
- Availability of a live webcast and replay ensures broader access to the event's insights.
- The announcement lacks specific financial or clinical data that could provide more substantial insights into company performance.
- No new product updates or significant business developments were disclosed, which might be seen as a lack of progress by some investors.
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs 45th Annual Global Healthcare Conference to be held in Miami, Florida on Monday, June 10, 2024, from 10:00-10:35 AM Eastern Time. Company management will also participate in one-on-one meetings with investors during the conference.
A live audio webcast of the event will be available to investors and other interested parties on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for 90 days.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Pamrevlumab, a fully human anti-CTGF monoclonal antibody, is in clinical development for the treatment of metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer (LAPC). Roxadustat (爱瑞卓®, EVRENZOTM) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com.
Contacts:
FibroGen, Inc.
Investors:
David DeLucia, CFA
Vice President of Corporate FP&A / Investor Relations
ir@fibrogen.com
Media:
Simon Miller
Commercial and External Communications
media@fibrogen.com
FAQ
When will FibroGen present at the Goldman Sachs 45th Annual Global Healthcare Conference?
Who will represent FibroGen at the Goldman Sachs 45th Annual Global Healthcare Conference?
Where is the Goldman Sachs 45th Annual Global Healthcare Conference being held?
Will FibroGen's presentation at the conference be available online?
What is the stock symbol for FibroGen?
